[HTML][HTML] Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
BF Haynes, K Wiehe, P Borrow, KO Saunders… - Nature Reviews …, 2023 - nature.com
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
[HTML][HTML] HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens
Humanity is currently facing the challenge of two devastating pandemics caused by two very
different RNA viruses: HIV-1, which has been with us for decades, and SARS-CoV-2, which …
different RNA viruses: HIV-1, which has been with us for decades, and SARS-CoV-2, which …
[HTML][HTML] Tailored immunogens direct affinity maturation toward HIV neutralizing antibodies
Induction of broadly neutralizing antibodies (bnAbs) is a primary goal of HIV vaccine
development. VRC01-class bnAbs are important vaccine leads because their precursor B …
development. VRC01-class bnAbs are important vaccine leads because their precursor B …
[HTML][HTML] HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design
Eliciting HIV-1-specific broadly neutralizing antibodies (bNAbs) remains a challenge for
vaccine development, and the potential of passively delivered bNAbs for prophylaxis and …
vaccine development, and the potential of passively delivered bNAbs for prophylaxis and …
[HTML][HTML] Determinants of HIV-1 broadly neutralizing antibody induction
Broadly neutralizing antibodies (bnAbs) are a focal component of HIV-1 vaccine design, yet
basic aspects of their induction remain poorly understood. Here we report on viral, host and …
basic aspects of their induction remain poorly understood. Here we report on viral, host and …
Vaccines and broadly neutralizing antibodies for HIV-1 prevention
Development of improved approaches for HIV-1 prevention will likely be required for a
durable end to the global AIDS pandemic. Recent advances in preclinical studies and early …
durable end to the global AIDS pandemic. Recent advances in preclinical studies and early …
[HTML][HTML] Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
NN Mkhize, AEJ Yssel, H Kaldine… - PLoS …, 2023 - journals.plos.org
The VRC01 Antibody Mediated Prevention (AMP) efficacy trials conducted between 2016
and 2020 showed for the first time that passively administered broadly neutralizing …
and 2020 showed for the first time that passively administered broadly neutralizing …
HIV broadly neutralizing antibody targets
Progress in the last year has provided support for the use of rationally stabilized whole HIV-1
trimers as immunogens for eliciting antibodies to multiple epitopes. Furthermore, the …
trimers as immunogens for eliciting antibodies to multiple epitopes. Furthermore, the …
[HTML][HTML] To bnAb or not to bnAb: defining broadly neutralising antibodies against HIV-1
SA Griffith, LE McCoy - Frontiers in immunology, 2021 - frontiersin.org
Since their discovery, antibodies capable of broad neutralisation have been at the forefront
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …
[HTML][HTML] Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01 …
KH Mayer, KE Seaton, Y Huang, N Grunenberg… - PLoS …, 2017 - journals.plos.org
Background VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that
is active against a broad range of HIV-1 primary isolates in vitro and protects against simian …
is active against a broad range of HIV-1 primary isolates in vitro and protects against simian …